These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 32927003

  • 1. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J, Kutter JP, Mu H, Moodley A, Yang M.
    Int J Pharm; 2020 Nov 30; 590():119877. PubMed ID: 32927003
    [Abstract] [Full Text] [Related]

  • 2. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X, Vogt FG, Hayes D, Mansour HM.
    Eur J Pharm Sci; 2014 Feb 14; 52():191-205. PubMed ID: 24215736
    [Abstract] [Full Text] [Related]

  • 3. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections.
    Saha T, Lyons N, Yue Yung DB, Quiñones-Mateu ME, Pletzer D, Das SC.
    Eur J Pharm Biopharm; 2024 Feb 14; 195():114170. PubMed ID: 38128743
    [Abstract] [Full Text] [Related]

  • 4. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HDC.
    J Pharm Sci; 2018 Aug 14; 107(8):2172-2178. PubMed ID: 29698726
    [Abstract] [Full Text] [Related]

  • 5. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N, Ahn P, Park H, Bhujbal S, Zemlyanov D, Cavallaro A, Mangal S, Li J, Zhou QT.
    Mol Pharm; 2018 Sep 04; 15(9):4004-4020. PubMed ID: 30028947
    [Abstract] [Full Text] [Related]

  • 6. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations.
    Hassan A, Farkas D, Longest W, Hindle M.
    Int J Pharm; 2020 Dec 15; 591():120027. PubMed ID: 33130220
    [Abstract] [Full Text] [Related]

  • 7. Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin.
    Pathak V, Park H, Zemlyanov D, Bhujbal SV, Ahmed MU, Azad MAK, Li J, Zhou QT.
    Pharm Res; 2022 Nov 15; 39(11):2781-2799. PubMed ID: 35915320
    [Abstract] [Full Text] [Related]

  • 8. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT, Sun SP, Chan JG, Wang P, Barraud N, Rice SA, Wang J, Li J, Chan HK.
    Mol Pharm; 2015 Aug 03; 12(8):2594-603. PubMed ID: 25423590
    [Abstract] [Full Text] [Related]

  • 9. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK.
    Eur J Pharm Biopharm; 2019 Sep 03; 142():543-552. PubMed ID: 31398437
    [Abstract] [Full Text] [Related]

  • 10. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
    Mangal S, Huang J, Shetty N, Park H, Lin YW, Yu HH, Zemlyanov D, Velkov T, Li J, Zhou QT.
    Int J Pharm; 2019 Apr 20; 561():102-113. PubMed ID: 30797863
    [Abstract] [Full Text] [Related]

  • 11. Synergistic combination of antimicrobial peptide and isoniazid as inhalable dry powder formulation against multi-drug resistant tuberculosis.
    Shao Z, Tam KK, Achalla VPK, Woon ECY, Mason AJ, Chow SF, Yam WC, Lam JKW.
    Int J Pharm; 2024 Apr 10; 654():123960. PubMed ID: 38447778
    [Abstract] [Full Text] [Related]

  • 12. Co-spray dried inhalable composite powders of ciprofloxacin and alginate oligosaccharide as anti-biofilm therapy.
    Zhang L, Bera H, Guo Y, Shi C, Ulrik Lind J, Radeke C, Wang J, Wang H, Zhao X, Cun D, Yang M.
    Int J Pharm; 2024 Apr 10; 654():123949. PubMed ID: 38417723
    [Abstract] [Full Text] [Related]

  • 13. Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.
    Alhajj N, O'Reilly NJ, Cathcart H.
    Int J Pharm; 2022 Apr 25; 618():121657. PubMed ID: 35288220
    [Abstract] [Full Text] [Related]

  • 14. Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying.
    Lu W, Rades T, Rantanen J, Yang M.
    Int J Pharm; 2019 Jun 30; 565():1-8. PubMed ID: 30999050
    [Abstract] [Full Text] [Related]

  • 15. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
    Momin MAM, Sinha S, Tucker IG, Doyle C, Das SC.
    Int J Pharm; 2017 Aug 07; 528(1-2):107-117. PubMed ID: 28583333
    [Abstract] [Full Text] [Related]

  • 16. Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Drug Pair Limiting the Development of Resistance.
    Wang J, Stegger M, Moodley A, Yang M.
    Pharmaceutics; 2023 Feb 21; 15(3):. PubMed ID: 36986580
    [Abstract] [Full Text] [Related]

  • 17. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L, Sun S, Parumasivam T, Denman JA, Gengenbach T, Tang P, Mao S, Chan HK.
    Eur J Pharm Biopharm; 2016 May 21; 102():132-41. PubMed ID: 26970252
    [Abstract] [Full Text] [Related]

  • 18. Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy.
    Lee SH, Teo J, Heng D, Ng WK, Zhao Y, Tan RB.
    J Pharm Sci; 2016 Apr 21; 105(4):1501-12. PubMed ID: 27019964
    [Abstract] [Full Text] [Related]

  • 19. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X, Vogt FG, Hayes D, Mansour HM.
    J Pharm Sci; 2014 Sep 21; 103(9):2937-2949. PubMed ID: 24740732
    [Abstract] [Full Text] [Related]

  • 20. Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles.
    Marasini N, Sheikh Z, Wong CYJ, Hosseini M, Spicer PT, Young P, Xin Ong H, Traini D.
    Int J Pharm; 2022 Aug 25; 624():121989. PubMed ID: 35809834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.